anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:A highly safe anti-inflammatory agent, containing 2-benzylaminopyrimidine or a pharmacologically acceptable salt thereof as an active constituent, having improved anti-inflammatory action, and exhibiting remarkable analgesic and antipyretic action with low toxicity. CONSTITUTION:An anti-inflammatory agent containing 2-benzylaminopyrimidine of the formula or a pharmacologically acceptable salt thereof, e.g. hydrochloride, hydrobromide or citrate, as an active constituent. The compound has improved anti-inflammatory action and exhibits remarkable analgesic and antipyretic action on pains and pyrexia due to the inflammation and low toxicity. The safety is much higher than aspirin, and flufenamic acid. The compound of the formula in about 5-80wt%, preferably about 40-60wt% concentration may be contained in the agent as the active constituent.
This study investigates abnormalities in cerebellar-cerebral static and dynamic functional connectivity among patients with acute pontine infarction, examining the relationship between these connectivity changes and behavioral dysfunction. Resting-state functional magnetic resonance imaging was utilized to collect data from 45 patients within seven days post-pontine infarction and 34 normal controls. Seed-based static and dynamic functional connectivity analyses identified divergences in cerebellar-cerebral connectivity features between pontine infarction patients and normal controls. Correlations between abnormal functional connectivity features and behavioral scores were explored. Compared to normal controls, left pontine infarction patients exhibited significantly increased static functional connectivity within the executive, affective-limbic, and motor networks. Conversely, right pontine infarction patients demonstrated decreased static functional connectivity in the executive, affective-limbic, and default mode networks, alongside an increase in the executive and motor networks. Decreased temporal variability of dynamic functional connectivity was observed in the executive and default mode networks among left pontine infarction patients. Furthermore, abnormalities in static and dynamic functional connectivity within the executive network correlated with motor and working memory performance in patients. These findings suggest that alterations in cerebellar-cerebral static and dynamic functional connectivity could underpin the behavioral dysfunctions observed in acute pontine infarction patients.
Compositions of matter comprising glycosphingolipids useful for suppressing an immune response having formula (I) wherein x is (a) or (b) or H; wherein Y is (c) or H; wherein m is 10 to 20; and wherein n is 1 to 14. Also presented are methods for suppressing an immune response in an animal employing glycosphingolipids as shown above. Synthetic gangliosides having artificial hydrophobic anchors, useful for suppressing an immune response having formula (II) wherein A is a carbohydrate moiety of a ganglioside, n is 5 to 20 and m is 5 to 20. Also presented are methods for suppressing an immune response in an animal and compositions of matter employing synthetic gangliosides having artificial hydrophobic anchors, as shown above. Simplified carbohydrate moiety- gangliosides, useful for suppressing an immune response according to formula (III) wherein B is a ceramide moiety of a ganglioside. Also presented are methods for suppressing an immune response in an animal and compositions of matter employing simplified carbohydrate moiety-ganglioside as shown above.
This is a two-stage study. The first stage is in a three-tier dose escalation format, followed by a second stage during which subjects will be randomized in an equal proportion to up to 3 qualifying dose arms.
Post-traumatic stress disorder (PTSD) is characterized by three symptom groupings: re-experiencing symptoms including flashbacks, nightmares, and intrusive memories; physiological hyperarousal; and avoidance symptoms. Of the three major categories of symptoms in PTSD listed by the Diagnostic and Statistical Manual of Mental Disorders, sleep-related problems are listed in two of them: difficulty falling asleep is considered an aspect of hyperarousal symptoms, and nightmares are a type of re-experiencing symptom. Both are found commonly in PTSD. Little is known about the relationship of neuroendocrine dysregulation in PTSD and sleep disturbance. It is possible that successful treatment of sleep disturbance in PTSD may alter an abnormal stress hormone pattern. The novel cyclopyrrolone hypnotic eszopiclone thus presents an intriguing opportunity to examine the treatment of sleep disturbances and nightmares in PTSD. This study will determine the safety, efficacy and impact on neuroendocrine parameters of eszopiclone compared to placebo for sleep disturbance and overall PTSD symptoms in individuals with PTSD and reported sleep disturbance.
A safe and relatively simple method is presented for the preparation of topically applied compositions used for the treatment of pain, especially sympathetically mediated pain, regardless of cause, in persons of either sex. The method utilizes the periodic application of topical compositions containing three classes of therapeutically effective agents prepared in suitable bases, to the skin areas affected by the pain. The three classes of therapeutic active agents are NMDA receptor antagonists, anticholinergic agents and sympathetic blocking agents. Each can be used alone or in combinations. The method provides significant pain relief which begins within minutes and lasts greater than 2 hours. The prepared compositions are non-toxic and have minimal side effects. No habit forming or addicting medications are used as therapeutically active ingredients. The prepared compositions can be self-administered or can be administered by another person at home or in any locale. Finally, the use of this method provides a previously unavailable means of treating patients with pain, especially sympathetically mediated pain.
A sucralfate self-emulsifying microcapsule is composed of solid powder or particles prepared from sucralfate, lipid, surfactant, and a wall material; the capsule core is composed of a sucralfate self-emulsifying composition, and the capsule core is wrapped by a wall material. The microcapsule is prepared through a spray drying method and a spray-coagulation method. The provided microcapsule is a novel upper digestive tract mucosa protective agent. The microcapsule has the advantages of wide range of indication, more unique and comprehensive action mechanism, and no prominent clinical side effect. Moreover, the frequency of daily drug taking is reduced by 50%, compared with conventional dosage forms. The microcapsule is user-friendly. The compliance of patients is increased, and the microcapsule is beneficial for more clinical patients. The particles in microcapsule are small, have a self-emulsifying function, are not affected by the gastrointestinal functions of patients, and can be well absorbed, and thus a good treatment effect can be achieved. The microcapsule is especially suitable for children, the old, and the patients, who have bad gastrointestinal functions, and can reduce the burden on stomach and intestines.
Cyanocobalamin Injection, USP is a sterile solution of cyanocobalamin for intramuscular or subcutaneous injection. Each mL contains 1000 mcg cyanocobalamin.

Each vial also contains Sodium Chloride, 0.9%. Benzyl Alcohol, 1.5%, is present as a preservative and Water for Injection q.s. Hydrochloric acid and/or sodium hydroxide may have been added during manufacture to adjust the pH (range 4.5-7.0).

Cyanocobalamin appears as dark red crystals or as an amorphous or crystalline red powder. It is very hygroscopic in the anhydrous form, and sparingly soluble in water (1:80). It is stable to autoclaving for short periods at 121°C. The vitamin B12 coenzymes are very unstable in light.

The chemical name is 5,6-dimethyl-benzimidazolyl cyanocobamide; the molecular formula is C63H88CoN14O14P. The cobalt content is 4.34%. The molecular weight is 1355.39.

The structural formula is represented below.
Consented parents of a concussed high school student who will receive the CDC Head's Up Concussion Guidelines and intervention RTL Student Protocol during a five week program. 75 Participants.
The purpose of this study is to test an intervention to reduce distracted driving among high school students. We're interested in learning the use of Do Not Disturb While Driving (DNDWD) by high school students. Participants will be recruited to participate into a 4-week study. Those that consent will download a driving app that will monitor their phone use while driving. Halfway through the monitoring period, we will ask participants to turn on DNDWD. Participants will also have the opportunity to enroll into an auto-reply message contest for best message. Once the 4- week monitoring period is complete participants will complete and exit survey
Maternal obesity is known to increase the risk of psychiatric disorders, such as anxiety, depression, schizophrenia and autism spectrum disorder in the offspring. While preventive measures are well-documented, practical approaches for addressing the damages once they are already established are limited. We have recently demonstrated the interplay between maternal obesity and treatment with cannabidiol (CBD) on neuroinflammation and peripheral metabolic disturbances during adolescence, however, it is known that both factors tend to vary throughout life. Therefore, here we investigated the potential of CBD to mitigate these alterations in the adult offspring of obese dams. Female Wistar rats were fed a cafeteria diet for 12 weeks prior to mating, and during gestation and lactation. Offspring received CBD (50 mg/kg) for 3 weeks from the 70th day of life. Behavioral tests assessed anxiety-like manifestations and social behavior, while neuroinflammatory and endocannabinoid markers were evaluated in the hypothalamus, prefrontal cortex (PFC) and hippocampus, as well as the biochemical profile in the plasma. CBD treatment attenuated maternal obesity-induced anxiety-like and social behavioral alterations, restoring exacerbated astrocytic and microglial markers in the hypothalamus, PFC and hippocampus of the offspring, as well as endocannabinoid levels in the PFC, with notable sex differences. Additionally, CBD attenuated plasma glucose and lipopolysaccharides (LPS) concentrations in females. These findings underscore the persistent influence of maternal obesity on the offspring's health, encompassing metabolic irregularities and behavioral impairments, as well as the role of the endocannabinoid system in mediating these outcomes across the lifespan.
The recommended dose of AXERT® (almotriptan malate) in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. As individuals may vary in their response to different doses of AXERT®, the choice of dose should be made on an individual basis.

If the headache is relieved after the initial AXERT® dose but returns, the dose may be repeated after 2 hours. The effectiveness of a second dose has not been established in placebo-controlled trials. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established.
Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
Arm description: Niraparib 200 mg, capsules, orally, once daily. For adult participants weighing 77 kilograms (kg) or more and with platelet count 150,000/mcrL or higher before the first dose of this drug, niraparib 300 mg, capsules, orally, once daily.
The invention relates to a medicine, and in particular relates to a traditional Chinese medicine for treating pharyngitis. Aiming at the characteristics of modern western medicines which are mainly used for treating according to symptoms and have the disadvantages of being non-ideal in effect and easy to relapse after healing, the invention provides the traditional Chinese medicine for treating pharyngitis. The traditional Chinese medicine disclosed by the invention can be used for effectively solving the problems of being incomplete in etiological treatment and easy to relapse in existing western medicine treatment. The technical scheme for solving the problems is as follows: the traditional Chinese medicine for treating pharyngitis is prepared from the following components in parts by weight: 75-85 parts of red wine, 40-60 parts of American ginseng, 40-60 parts of Chinese angelica, 130-150 parts of blackberry lily, and 250-400 parts of subprostrate sophora. The traditional Chinese medicine is prepared only by grinding American ginseng, Chinese angelica, blackberry lily and subprostrate sophora into powder and uniformly mixing. The traditional Chinese medicine is taken with red wine. The traditional Chinese medicine disclosed by the invention is scientific in compatibility, reasonable in use amount, easy to prepare, low in cost, convenient to use and good in curative effect; the traditional Chinese medicine is prepared by adopting traditional Chinese medicines having the effects of nourishing yin, increasing fluid, clearing heat, eliminating phlegm, wetting throat and relieving sore-throat; and thus, the traditional Chinese medicine has good effects for treating pharyngitis.
<P>PROBLEM TO BE SOLVED: To provide a hard tablet that can be stored, packaged and processed in bulk.  <P>SOLUTION: The present invention provides the tablet created from an active ingredient mixed into a matrix of an indirect compression filler and a relatively high lubricant content. The tablet also contains a matrix comprising the indirect compression filler, a wicking agent, and a hydrophobic lubricant. The matrix of the tablet contains a quick water-soluble ingredient in at least about 60% based on the total weight of the tablet. It is preferable that the tablet dissolves rapidly in the mouth of the patient with a minimum of grit.  <P>COPYRIGHT: (C)2008,JPO&INPIT
A mobile device for detecting an electrical signal generated by an ingestible event marker is disclosed. The mobile device includes a detection subsystem to receive an electrical signal generated by an ingestible event marker from a detection arrangement. A processing subsystem is coupled to the detection subsystem to decode the electrical signal. A radio subsystem is configured to transmit the decoded electrical signal to a wireless node. A system includes the mobile device and the detection arrangement. A method includes receiving the electrical signal generated by the ingestible event marker at the mobile device, decoding the electrical signal to extract information associated with the ingestible event marker, and transmitting the information to a wireless node.
NOT FOR INJECTION. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections. Acute purulent or parasitic infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication.

Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation.

If this product is used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. IOP should be checked frequently.

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

Products containing neomycin sulfate may cause cutaneous sensitization. Sensitivity to topically administered aminoglycosides, such as neomycin, may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If hypersensitivity develops during use of the product, treatment should be discontinued. Cross-hypersensitivity to other aminoglycosides can occur, and the possibility that patients who become sensitized to topical neomycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to cardiovascular surgery. Multispiral computed tomography of the chest organs is performed against the background of intravenous administration of non-ionic contrast agents at a rate of no more than 2 ml/kg of body weight using automatic injectors. Each pulmonary vein is measured at several levels: from the fusion of the pulmonary veins at the level of the segmental ones with the lobar veins - the bifurcation of the pulmonary veins, the lobar veins at the level of the flow of the pulmonary veins into the atrium - the mouth of the pulmonary veins. At each of the levels, the cross-sectional area of ​​the pulmonary vein is determined in a plane perpendicular to the pulmonary vein. The smallest vein area is taken into account as the smallest level of vein throughput. The formula for calculating the pulmonary venous index (PVI) includes the areas of the pulmonary veins in the narrowest and, accordingly, hemodynamically significant areas. Thus, PVI is calculated as the sum of the cross-sectional areas of the pulmonary veins, correlated to the body surface area, determine and sum up the cross-sectional areas of four pulmonary veins - the right upper and lower lobe, left upper and lower lobe veins. If the PVI is less than 204.950 mm2/m2, then the Fontaine operation is not indicated for the patient.EFFECT: method makes it possible to make a decision on the admissibility of performing the Fontan operation in patients with a functionally single ventricle of the heart.1 cl, 1 ex
Both groups will participate in 60 hours of intensive therapy over 10 days at SRC (6 hours per day Monday-Friday) following the established 'Pirate Camp' CIMT protocol. The full protocol can be found at: https://twu.edu/occupational-therapy/Camp-Based-Augmented-CIMT-Guide/. Both groups will participate in child friendly outdoor and indoor activities that promote the use of the involved side for example; parachute games, sock toss, penny pick up.
Patients receive oblimersen IV continuously on days 1-5 and gemcitabine IV over 2-3 hours on day 5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
Depression in youth is a recurrent and impairing disorder. Although some treatments have shown modest effects in children and adolescents (e.g., cognitive behavioral therapy -- CBT), there remains a critical need to build upon these therapies in order to reach even more youths with depression. One variable hypothesized to affect children's interpersonal relationships is their level of social cognitive development on abilities particularly relevant to social functioning and CBT (e.g., social perspective taking; theory of mind). The first RCT (R61) will test the efficacy of an intervention aimed at increasing children's social cognitive (SC) abilities.Youth (ages 12-17; N=42) with depression diagnoses or clinical levels of depressive symptoms (CESD \> 20) will be randomized to either the social cognitive training enhanced CBT (SCT-CBT) or CBT only. Pre- and post-treatment evaluations will assess the social cognitions. In the second RCT (R33), we will conduct a replication trial with a new sample of 82 youth (ages 12-17) again randomized to SCT-CBT or CBT only. Youth will be evaluated with regard to the SC abilities (i.e., theory of mind), level of depressive symptoms, and social functioning at baseline, post-treatment, and at a 4-month follow-up (R33). Finally, in the R33 we will test if increases in SC abilities partially account for the relation between treatment condition and decreases in depression. If the SCT-CBT intervention significantly improves children's SC abilities and social functioning and decreases depression, then this will provide therapists with a more efficient and personalized treatment of depression in youth,
It includes 20 patients who will not receive any physiotherapy intervention. They will receive medical treatment only and will act as a control group.
FIELD: medicine. SUBSTANCE: desired product having empirical formula C 19 H 17 N 3 OS and structural formula I has melting point 172 C, its yield being 88% . Compound having structural formula II is used as reagent 1, CH 3 J is used as reagent 2. Reaction is carried out in the presence of alkali or alkali metal carbonates at room temperature in aqueous, aqueous-alcohol medium or in dimethylformamide. Formulae I and II are given in specification. EFFECT: improves desired product quality. 1 tbl
BACKGROUND AND AIMS: Anti-angiogenic therapies prolong patient survival in some malignancies but not glioblastoma. We focused on the relationship between the differentiation of glioma stem like cells (GSCs) into tumor derived endothelial cells (TDECs) and, anti-angiogenic therapy resistance. Especially we aimed to elucidate the mechanisms of drug resistance of TDECs to anti-angiogenic inhibitors and identify novel anti-angiogenic drugs with clinical applications.
RESULTS: The mouse GSCs, 005, were differentiated into TDECs under hypoxic conditions, and TDECs had endothelial cell characteristics independent of the vascular endothelial growth factor (VEGF) pathway. In vivo, inhibition of the VEGF pathway had no anti-tumor effect and increased the percentage of TDECs in the 005 mouse model. Novel anti-angiogenic drugs for glioblastoma were evaluated using a tube formation assay and a drug repositioning strategy with existing blood-brain barrier permeable drugs. Drug screening revealed that the antidepressant sertraline inhibited tube formation of TDECs. Sertraline was administered to differentiated TDECs in vitro and 005 mouse models in vivo to evaluate genetic changes by RNA-Seq and tumor regression effects by immunohistochemistry and MRI. Sertraline reduced Lama4 and Ang2 expressions of TDEC, which play an important role in non-VEGF-mediated angiogenesis in tumors. The combination of a VEGF receptor inhibitor axitinib, and sertraline improved survival and reduced tumor growth in the 005 mouse model.
CONCLUSION: Collectively, our findings showed the diversity of tumor vascular endothelial cells across VEGF and non-VEGF pathways led to anti-angiogenic resistance. The combination of axitinib and sertraline can represent an effective anti-angiogenic therapy for glioblastoma with safe, low cost, and fast availability.
Monotherapy with MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, in participants with histologically or cytologically-confirmed advanced/metastatic solid tumor, and who and have received, been intolerant to, been ineligible for, or refused all treatment known to confer clinical benefit. MK-4830A will be administered IV, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days.